Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Thursday, Benzinga reports. The firm currently has a $24.00 price objective on the stock.

Separately, Mizuho reduced their price objective on shares of Vigil Neuroscience from $15.00 to $13.00 in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $18.40.

Vigil Neuroscience Stock Up 18.7 %

Shares of NASDAQ VIGL opened at $6.79 on Thursday. The firm’s 50-day simple moving average is $6.83 and its 200 day simple moving average is $8.74. The company has a market cap of $243.56 million, a price-to-earnings ratio of -3.33 and a beta of 2.89. Vigil Neuroscience has a 12-month low of $4.68 and a 12-month high of $16.77.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, equities analysts expect that Vigil Neuroscience will post -2.17 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Vigil Neuroscience in the first quarter worth about $94,000. Citigroup Inc. acquired a new position in shares of Vigil Neuroscience in the first quarter valued at approximately $451,000. BlackRock Inc. acquired a new position in shares of Vigil Neuroscience in the first quarter valued at approximately $2,135,000. Vanguard Group Inc. bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $2,708,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $135,000. Institutional investors own 71.80% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.